ReviewFrontiers in oncology2022
Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A comprehensive analysis and visualization of immune-related adverse events in lung cancer immunotherapy a bibliometric study.Discover oncology · 2026Review
- Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors.Current oncology (Toronto, Ont.) · 2026Review
- Salvage sleeve-pneumonectomy for a malignant bronchomediastinal fistula and the feasibility of a modified tritubeJournal of cardiothoracic surgery · 2026Article
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Incidence and risk factors of infections in lung cancer patients receiving immunotherapy combined with chemotherapy: a real-world retrospective study.American journal of cancer research · 2026Article
- Risk factors and nomogram prediction model for checkpoint inhibitor-related pneumonitis in patients with advanced non-small cell lung cancer.Frontiers in medicine · 2026Article
- COVID-19 and Lung Cancer Interactions: A Literature Review.Medical sciences (Basel, Switzerland) · 2025Review
- Premature Pembrolizumab-Induced Pulmonary Problems: A Case of Atypical Early-Onset Checkpoint Inhibitor Pneumonitis.Cureus · 2025Article
- Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies.Biological procedures online · 2025Review
- Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.Immunotherapy · 2024Article
- Toxicity in the era of immune checkpoint inhibitor therapy.Frontiers in immunology · 2024Review
- Successful management of Epstein‑Barr virus‑associated severe checkpoint inhibitor‑related pneumonitis: A case report.Experimental and therapeutic medicine · 2023Article
- [A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population.Journal of thoracic disease · 2023Article
- Nanoparticles overcome adaptive immune resistance and enhance immunotherapyFrontiers in pharmacology · 2023Review
- Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have shown definite therapeutic effects in various types of cancers, especially non-small cell lung cancer (NSCLC). However, ICIs have unique side effects, called immune-related adverse events (irAEs), which can occur in various systems throughout the body. Among such irAEs, immune checkpoint inhibitor-related pneumonitis (ICI-P) is a fatal adverse reaction. In this review, we discussed the risk factors, pathogenesis, clinical characteristics, radiological manifestations, pathological features, diagnosis, grading, and management of ICI-P in NSCLC and the relationship between ICI-P and the efficacy of ICI therapy. In addition, we discussed the predictive factors for ICI-P. This review will play a crucial role in the prediction, evaluation, and management of ICI-P for widespread application of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.